Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG), also known as PI3Kγ or p110γ, is a class IB phosphoinositide 3-kinase (PI3K) that plays a crucial role in immune cell signaling, inflammation, and cardiovascular function. Unlike class IA PI3Ks, which are primarily activated by receptor tyrosine kinases, PI3Kγ is uniquely activated by G-protein coupled receptors (GPCRs) via Gβγ subunits. It phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which recruits downstream effectors like AKT to promote cell survival, growth, and migration. In the tumor microenvironment, PI3Kγ is highly expressed in myeloid cells, such as tumor-associated macrophages (TAMs), where it promotes an immunosuppressive M2-like phenotype that helps tumors evade immune surveillance. Consequently, targeting PI3Kγ with selective inhibitors like eganelisib (IPI-549) or dual inhibitors like duvelisib is a promising therapeutic strategy to reprogram the tumor microenvironment, enhance anti-tumor immunity, and overcome resistance to immune checkpoint inhibitors. However, therapeutic targeting of PI3K isoforms is associated with notable safety concerns, including autoimmune-like toxicities such as colitis, pneumonitis, and hepatotoxicity, as well as metabolic side effects.
Selective inhibition of PI3K-gamma or dual inhibition of PI3K-delta and PI3K-gamma to disrupt downstream AKT signaling, reprogram tumor-associated macrophages, and reduce inflammatory cell migration.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG).